FLNA FILANA THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1069530 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY60.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-60.5%
ROA-36.7%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets42.1%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.68x
Accruals ratio-11.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $26.59M | $69.64M | $89.42M | $68.03M | $24.81M |
| SG&A expense | $68.80M | $71.81M | $16.53M | $11.99M | $8.05M |
| Operating income | -$95.39M | -$141.45M | -$105.96M | -$80.02M | -$32.87M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -$32.38M |
| EBITDA | -$94.49M | -$140.49M | -$104.87M | -$79.22M | -$32.56M |
| EPS (basic) | -1.88 | -0.53 | -2.32 | -1.90 | -0.82 |
| EPS (diluted) | -1.88 | -1.46 | -2.32 | -1.90 | -0.82 |
| Weighted avg. shares (diluted) | 48.30M | 46.60M | 41.93M | 40.20M | 39.41M |
| Balance sheet | |||||
| Cash & equivalents | $95.50M | $128.57M | $121.14M | $201.01M | $233.44M |
| Current assets | $97.71M | $136.53M | $129.63M | $211.23M | $244.48M |
| PP&E, net | $20.65M | $21.00M | $21.85M | $22.86M | $20.62M |
| Intangibles | $193,000 | $37,000 | $176,000 | $622,000 | $1.07M |
| Total assets | $118.36M | $157.53M | $151.66M | $234.83M | $266.78M |
| Current liabilities | $43.83M | $11.75M | $14.20M | $7.06M | $12.53M |
| Total liabilities | $43.95M | $11.83M | $14.20M | $7.29M | $12.87M |
| Shareholders' equity | $74.40M | $145.70M | $137.47M | $227.54M | $253.91M |
| Shares outstanding | 48.31M | 48.20M | 42.24M | 41.74M | 40.02M |
| Cash flow statement | |||||
| Operating cash flow | -$32.25M | -$116.93M | -$82.03M | -$77.51M | -$30.20M |
| Capital expenditure | $581,000 | $103,000 | $414,000 | $2.71M | $22.21M |
| Free cash flow | -$32.83M | -$117.03M | -$82.44M | -$80.23M | -$52.41M |
| Investing cash flow | -$581,000 | -$103,000 | -$414,000 | -$2.71M | -$22.21M |
| Financing cash flow | -$239,000 | $124.47M | $2.56M | $47.80M | $192.34M |
| Depreciation & amortization | $903,000 | $952,000 | $1.08M | $804,000 | $310,000 |
| Stock-based compensation | $19.58M | $16.29M | $4.59M | $2.07M | $1.76M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.